HC Wainwright Forecasts OmniAb's Q3 Earnings (NASDAQ:OABI)

Key Points

• HC Wainwright lowered its Q3 2026 EPS forecast for OmniAb to a loss of $0.11 per share from a previous estimate of $0.10, while projecting a gradual path toward profitability by 2030.
• OmniAb’s latest quarterly results beat expectations, reporting a $0.05-per-share loss versus the anticipated $0.12 loss and revenue of $13.41 million against a $4.69 million estimate.
• Analyst sentiment remains mixed, with one Buy and one Sell rating producing a consensus Hold rating; Weiss Ratings also downgraded the stock from “sell (d-)” to “sell (e+).”

OmniAb, Inc. (NASDAQ:OABI - Free Report) - Equities research analysts at HC Wainwright reduced their Q3 2026 EPS estimates for OmniAb in a research note issued to investors on Friday, August 7th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of ($0.11) for the quarter, down from their previous estimate of ($0.10). The consensus estimate for OmniAb's current full-year earnings is ($0.39) per share. HC Wainwright also issued estimates for OmniAb's FY2026 earnings at ($0.34) EPS, FY2027 earnings at ($0.18) EPS, FY2028 earnings at ($0.06) EPS, FY2029 earnings at ($0.02) EPS and FY2030 earnings at $0.05 EPS.

OmniAb (NASDAQ:OABI - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.05) earnings per share for the quarter, beating analysts' consensus estimates of ($0.12) by $0.07. The business had revenue of $13.41 million during the quarter, compared to analyst estimates of $4.69 million. OmniAb had a negative net margin of 115.12% and a negative return on equity of 16.59%.

Separately, Weiss Ratings cut OmniAb from a "sell (d-)" rating to a "sell (e+)" rating in a research report on Thursday. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, OmniAb presently has a consensus rating of "Hold".

OmniAb Price Performance

OABI stock opened at $3.39 on Tuesday. The company has a market cap of $490.80 million, a P/E ratio of -9.42 and a beta of 0.45. OmniAb has a 1 year low of $1.30 and a 1 year high of $3.44. The stock's fifty day moving average price is $2.28 and its 200-day moving average price is $1.97.

Institutional Investors Weigh In On OmniAb

Hedge funds have recently modified their holdings of the business. Osaic Holdings Inc. raised its holdings in OmniAb by 214.4% in the 2nd quarter. Osaic Holdings Inc. now owns 14,247 shares of the company's stock worth $25,000 after purchasing an additional 9,716 shares during the period. AQR Capital Management LLC bought a new stake in OmniAb during the first quarter valued at about $25,000. BNP Paribas Financial Markets increased its position in OmniAb by 92.5% in the third quarter. BNP Paribas Financial Markets now owns 21,721 shares of the company's stock worth $35,000 after buying an additional 10,438 shares in the last quarter. State of Wyoming increased its position in OmniAb by 101.7% in the first quarter. State of Wyoming now owns 24,694 shares of the company's stock worth $39,000 after buying an additional 12,451 shares in the last quarter. Finally, Cerity Partners LLC raised its stake in shares of OmniAb by 111.5% in the second quarter. Cerity Partners LLC now owns 22,612 shares of the company's stock worth $39,000 after buying an additional 11,919 shares during the period. Institutional investors own 72.08% of the company's stock.

OmniAb Company Profile

OmniAb, Inc NASDAQ: OABI operates as a biotechnology company specializing in the discovery and development of therapeutic antibodies. The company’s integrated antibody discovery platform combines proprietary transgenic animal models, in vitro screening, and in silico engineering to accelerate lead identification and optimization. OmniAb offers both fee-for-service collaborations and license agreements, enabling biopharmaceutical partners to leverage its suite of technologies for programs spanning oncology, immunology, and other therapeutic areas.

Founded in 2016 and headquartered in Seattle, Washington, OmniAb went public in May 2021.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source